8 results on '"Prayer-Galetti T"'
Search Results
2. Anti PSMA immunotoxins activity against prostate cancer cell lines
- Author
-
Prayer Galetti, T., Pagano, F., Fracasso, Giulio, Cingarlini, Sara, Bellisola, Giuseppe, Righetti, Sabrina, Chiesa, Elena, and Colombatti, Marco
- Subjects
immunotoxins ,Prostate Specific Membrane Antigen (PSMA) ,ricin ,prostate cancer - Published
- 2002
3. Clinical and Pathological Characteristics of Patients Presenting with Biochemical Progression after Radical Retropubic Prostatectomy for Pathologically Organ-Confined Prostate Cancer.
- Author
-
Pinto, F., Prayer-Galetti, T., Gardiman, M., Sacco, E., Ciaccia, M., Fracalanza, S., Betto, G., and Pagano, F.
- Subjects
- *
PROSTATECTOMY , *PROSTATE surgery , *PROSTATE cancer , *PROSTATE-specific antigen , *TUMOR antigens - Abstract
Introduction: To identify risk factors for biochemical failure after radical prostatectomy (RP) in men with pathologically organ-confined (OC) prostate cancer (PCa). Materials and Methods: Clinical and pathological features of 350 consecutive patients with pathologically OC PCa treated only with RP and bilateral pelvic lymphadenectomy were analyzed, retrospectively, to identify predictor parameters of prostate-specific antigen (PSA) failure (PSA ≥0.4 ng/ml). The median follow-up was 58.6 months (range: 3.9–183 months). All pathological specimens were step sectioned at 4-mm intervals. Kaplan-Meier progression-free survival rates and χ2 test were adopted for statistical analyses. Multivariate Cox proportional hazard regression models were used to test the association between pathological Gleason score and surgical margin status. Results: 67 patients (19.1%) failed at a median follow-up of 40.2 months (range 1.9–123.3). Age and preoperative PSA failed to reveal significance also in patients with serum PSA ≥20 ng/ml (p = 0.46). Patients with T3 clinical stage had a higher progression rate compared to T1C and T2 (43.5 vs. 27.8 and 17.3%, respectively) even if no high statistical significance was pointed out. Presence of perineural infiltration (p = 0.04) and prostatic apex infiltration (p = 0.74) in the prostatectomy specimens failed to reveal significance. A high pathological Gleason score (≥7; p = 0.0003) and surgical margin status (p < 0.0001) were shown to be the most powerful predictive parameters of biochemical progression. Conclusions: In patients with pathologically OC PCa the presence of a high pathological Gleason score and positive surgical margins appear to represent the most important factors for prediction of outcome following RP. Copyright © 2006 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
4. Plasma Chromogranin A in Patients with Prostate Cancer Improves the Diagnostic Efficacy of Free/Total Prostate-Specific Antigen Determination.
- Author
-
Fracalanza, S., Prayer-Galetti, T., Pinto, F., Navaglia, F., Sacco, E., Ciaccia, M., Plebani, M., Pagano, F., and Basso, D.
- Subjects
- *
CHROMOGRANINS , *PROSTATE cancer , *EPITOPES , *BENIGN prostatic hyperplasia , *UROLOGY - Abstract
Introduction: We ascertained whether plasma chromogranin A enhances the power of serology assessing prostate cancer (PC). Materials andMethods: We studied 56 PC and 83 benign prostatic hyperplasia (BPH) patients. In the sera we measured total prostate-specific antigen (tPSA) and free PSA (fPSA) and calculated the ratio between fPSA and tPSA (f/tPSA). In plasma samples the levels of chromogranin A (CgA) were also assayed. Results: PC patients had higher CgA (p < 0.005) and tPSA (p < 0.05) levels, and a lower f/tPSA ratio (p < 0.001), than BPH patients. When f/tPSA and CgA were combined, the diagnostic sensitivity was enhanced (57–73%), while the specificity had only an 8% reduction (from 89 to 80%). CgA was only correlated to the Gleason PC score (p < 0.05). Conclusions: CgA determination in PC may enhance the diagnostic accuracy of the f/tPSA assay and provides useful information on the tumor grade. Copyright © 2005 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
5. Management of prostate-specific antigen relapse in prostate cancer: A European consensus.
- Author
-
Boccon-Gibod, L., Djavan, B., Hammerer, P., Hoeltl, W., Kattan, M.W., Prayer-Galetti, T., Teillac, P., and Tunn, U.W.
- Subjects
CANCER relapse ,PROSTATE cancer ,TUMOR antigens ,PROSTATECTOMY ,PROSTATE surgery ,RADIOTHERAPY ,COLD therapy - Abstract
A European Consensus on the management of prostate-specific antigen (PSA) relapse in patients with prostate cancer has been formulated. The key recommendations proposed are that total PSA is the best detection tool for prostate cancer, with free and complexed PSA having a role in the PSA range 1–4 ng/ml. PSA relapse after radical prostatectomy (RP) has been defined as a value of 0.2 ng/ml with one subsequent rise, while the ASTRO definition should be used after radiotherapy. A PSA level of less than 0.4 ng/ml after hormonal therapy can be considered an indicator of a positive response. Continuous assessment using nomograms or artificial neural networks will help to determine whether progression after local therapy is distant or local, which is the basis for treatment decisions. Secondary treatment after local failure of RP should be initiated when PSA levels reach 1.0–1.5 ng/ml and salvage radiotherapy can be considered with or without hormonal therapy. Local failure after radiotherapy can be treated with a choice of high-intensity-focused ultrasound, salvage RP (only in highly selected patients), cryotherapy or external beam radiation. Treatment of distant failure involves hormonal manipulation, the type and the timing of which is based on both physician and patient preferences. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
6. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N [ 4532).
- Author
-
Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C. V., Carbone, G. M., Cavalli, A., Pagano, F., Ragazzi, E., Prayer-Galetti, T., and Alimonti, A.
- Subjects
- *
SARS-CoV-2 , *COVID-19 , *ANDROGEN drugs , *PROSTATE-specific antigen , *PROSTATE cancer , *PROSTATE cancer patients , *ANGIOTENSIN converting enzyme - Abstract
Background: Cell entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on binding of the viral spike (S) proteins to angiotensin-converting enzyme 2 and on S protein priming by TMPRSS2. Inhibition of TMPRSS2 may work to block or decrease the severity of SARS-CoV-2 infections. Intriguingly, TMPRSS2 is an androgen-regulated gene that is up-regulated in prostate cancer where it supports tumor progression and is involved in a frequent genetic translocation with the ERG gene. First- or second-generation androgen-deprivation therapies (ADTs) decrease the levels of TMPRSS2. Here we put forward the hypothesis that ADTs may protect patients affected by prostate cancer from SARS-CoV-2 infections. Materials and methods: We extracted data regarding 9280 patients (4532 males) with laboratory-confirmed SARS-CoV- 2 infection from 68 hospitals in Veneto, one of the Italian regions that was most affected by the coronavirus disease 2019 (COVID-19) pandemic. The parameters used for each COVID-19-positive patient were sex, hospitalization, admission to intensive care unit, death, tumor diagnosis, prostate cancer diagnosis, and ADT. Results: There were evaluable 9280 SARS-CoV-2-positive patients in Veneto on 1 April 2020. Overall, males developed more severe complications, were more frequently hospitalized, and had a worse clinical outcome than females. Considering only the Veneto male population (2.4 million men), 0.2% and 0.3% of non-cancer and cancer patients, respectively, tested positive for SARS-CoV-2. Comparing the total number of SARS-CoV-2-positive cases, prostate cancer patients receiving ADT had a significantly lower risk of SARS-CoV-2 infection compared with patients who did not receive ADT (OR 4.05; 95% CI 1.55e10.59). A greater difference was found comparing prostate cancer patients receiving ADT with patients with any other type of cancer (OR 4.86; 95% CI 1.88e12.56). Conclusion: Our data suggest that cancer patients have an increased risk of SARS-CoV-2 infections compared with noncancer patients. However, prostate cancer patients receiving ADT appear to be partially protected from SARS-CoV-2 infections. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. MALDI-TOF peptidomic analysis of serum and post-prostatic massage urine specimens to identify prostate cancer biomarkers
- Author
-
Andrea Padoan, Filiberto Zattoni, Daniela Basso, Carlo-Federico Zambon, Dania Bozzato, Tommaso Prayer-Galetti, Rino Bellocco, Stefania Moz, Giorgio Arrigoni, Mario Plebani, Padoan, A, Basso, D, Zambon, C, Prayer-Galetti, T, Arrigoni, G, Bozzato, D, Moz, S, Zattoni, F, Bellocco, R, and Plebani, M
- Subjects
0301 basic medicine ,Serum ,medicine.medical_specialty ,Intraclass correlation ,Peptidomic profiling ,Data normalization ,Clinical Biochemistry ,Urology ,lcsh:Medicine ,Urine ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Analytical variability ,Measurement error ,Lower urinary tract symptoms ,Medicine ,Biomarker discovery ,Molecular Biology ,Reproducibility ,SIMEX ,business.industry ,Research ,lcsh:R ,General Medicine ,Biomarker ,medicine.disease ,MALDI-TOF/MS ,Prostate-specific antigen ,030104 developmental biology ,Regression calibration ,030220 oncology & carcinogenesis ,Molecular Medicine ,Biomarker (medicine) ,business ,Biomarkers - Abstract
Background Lower urinary tract symptoms (LUTS) and prostate specific antigen-based parameters seem to have only a limited utility for the differential diagnosis of prostate cancer (PCa). MALDI-TOF/MS peptidomic profiling could be a useful diagnostic tool for biomarker discovery, although reproducibility issues have limited its applicability until now. The current study aimed to evaluate a new MALDI-TOF/MS candidate biomarker. Methods Within- and between-subject variability of MALDI-TOF/MS-based peptidomic urine and serum analyses were evaluated in 20 and 15 healthy donors, respectively. Normalizations and approaches for accounting below limit of detection (LOD) values were utilized to enhance reproducibility, while Monte Carlo experiments were performed to verify whether measurement error can be dealt with LOD data. Post-prostatic massage urine and serum samples from 148 LUTS patients were analysed using MALDI-TOF/MS. Regression-calibration and simulation and extrapolation methods were used to derive the unbiased association between peptidomic features and PCa. Results Although the median normalized peptidomic variability was 24.9%, the within- and between-subject variability showed that median normalization, LOD adjustment, and log2 data transformation were the best combination in terms of reliability; in measurement error conditions, intraclass correlation coefficient was a reliable estimate when the LOD/2 was substituted for below LOD values. In the patients studied, 43 peptides were shared by the urine and serum, and several features were found to be associated with PCa. Only few serum features, however, show statistical significance after the multiple testing procedures were completed. Two serum fragmentation patterns corresponded to the complement C4-A. Conclusions MALDI-TOF/MS serum peptidome profiling was more efficacious with respect to post-prostatic massage urine analysis in discriminating PCa. Electronic supplementary material The online version of this article (10.1186/s12014-018-9199-8) contains supplementary material, which is available to authorized users.
- Published
- 2018
8. SC129 - Diagnostic results of 18F-choline PET/MRI for recurrent prostate cancer after radical prostatectomy.
- Author
-
Nguyen, A., Morlacco, A., Lacognata, C., Lauro, A., Zecchini, G., Prayer-Galetti, T., Zucchetta, P., Zattoni, F., and Novara, G.
- Subjects
- *
PROSTATE cancer , *PETS - Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.